Onconova Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch ONTX and buy or sell other stocks, ETFs, and their options commission-free!

About ONTX

Traws Pharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. It focuses on discovering and developing small molecule drug candidates to treat cancer. 

CEO
Iain David Dukes, PhD
CEOIain David Dukes, PhD
Employees
7
Employees7
Headquarters
Newtown, Pennsylvania
HeadquartersNewtown, Pennsylvania
Founded
1998
Founded1998
Employees
7
Employees7

ONTX Key Statistics

Market cap
3.88M
Market cap3.88M
Price-Earnings ratio
0.08
Price-Earnings ratio0.08
Dividend yield
Dividend yield
Average volume
299.73K
Average volume299.73K
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$8.61
52 Week high$8.61
52 Week low
$0.97
52 Week low$0.97

Stock Snapshot

As of today, Onconova Therapeutics(ONTX) shares are valued at $0.54. The company's market cap stands at 3.88M, with a P/E ratio of 0.08.

On 2026-02-03, Onconova Therapeutics(ONTX) shares started trading at —, with intraday highs of — and lows of —.

Trading activity shows a volume of 0, compared to an average daily volume of 299.73K.

The stock's 52-week range extends from a low of $0.97 to a high of $8.61.

The stock's 52-week range extends from a low of $0.97 to a high of $8.61.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.